Aspects described herein generally relate to methods of making a phosphono paraffin comprising forming a reaction mixture by mixing a haloparaffin, a phosphite, and sodium iodide. Methods comprise heating the reaction mixture to form the phosphono paraffin. Aspects described herein further relate to a phosphono paraffin represented by formula (I):

##STR00001##

wherein each instance of R.sup.1 is independently

##STR00002##

wherein each instance of R.sup.2 and R.sup.3 is independently linear or branched C.sub.1-20 alkyl, C.sub.1-20 cycloalkyl, or aryl; the number of instances where R.sup.1 is

##STR00003##

of formula (I) is between about 2 and about 8; and n is an integer between 4 and 22.

The present disclosure relates to a composition that includes a sequestering material capable of binding a target material, where the sequestering material includes a first component that includes at least one of a functional group, a molecule, an oligomer, or a polymer, and the target material includes at least one of an element, a chemical, and/or a compound. In some embodiments of the present disclosure, the element may include at least one element from at least one of Rows 4, 5, 6, and 7 of the Periodic Table and/or an inner transition metal.

In accordance with the disclosure, one aspect of the present application is directed to a lubricant additive composition. The lubricant additive composition includes a component or mixture of components selected from (a) an aminoalkylphosphonic acid dialkyl ester; (b) a cyclized product of an aminoalkylphosphonic acid dialkyl ester; and a mixture of (a) and (b). Preparation and use of the additive composition in a lubricant for antiwear and/or friction reduction are also disclosed.

The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.

Provided are: a composition for forming a hole transporting layer for perovskite solar cells, which is inexpensive and does not need to be used together with a dopant; and a compound which can be contained in a composition for forming a hole transporting layer. A compound represented by general formula (I) (wherein Ar represents an aryl group; A represents a structure represented by formula (II); Z's independently represent a hydrogen atom, a structure represented by general formula (III), or a structure represented by formula (IV), and maybe the same as or different from each other, wherein a case where each of Z's is a hydrogen atom is excluded; Y's independently represents at least one member selected from the group mentioned below; R.sup.1 and R.sup.2 independently represents a hydrogen atom, an alkyl group or an alkoxy group, or R.sup.1 and R.sup.2 may together form a ring having one or two oxygen atoms; ×'s independently represent an alkyl group, an alkoxy group, an alkylthio group, a monoalkylamino group or a dialkylamino group each of which may be substituted by a halogen atom; k represents 0 or 1; l represents 2 or 3; m represents an integer of 1 to 6; and r represents 1 or 2; wherein, when k is 0, 1 is 3, m is 1 and all of three bonds of A are bonded to Z.

##STR00001##

Trisubstituted triazine antioxidants.

Trisubstituted triazine antioxidants.

A non-aqueous electrolyte solution according to an embodiment of the present invention includes a non-aqueous organic solvent, a lithium salt and a phosphonate-based additive having a predetermined chemical structure. Surface damage and side reactions of the cathode active material can be suppressed by the phosphonate-based additive. According to an embodiment of the present invention, a lithium secondary battery including the non-aqueous electrolyte solution is provided.

The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

The present disclosure provides method of treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject, the method comprising administering a compound of Formula (I) as set forth in the specification. In one embodiment, the prokaryotic pathogen belongs to the genus Staphylococcus.